Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
deals
3
×
life sciences
national blog main
san francisco blog main
san francisco top stories
biotech
boston
clinical trials
eli lilly
investing
national top stories
roche
sanofi
amgen
avapritinib
biontech
blueprint medicines
boehringer ingelheim
cancer
cancer drugs
cobimetinib
cstone pharmaceuticals
curevac
european medicines agency
fda
fisogatinib
flatiron health
genentech
hepatocellular carcinoma
infectious diseases
ipo
jeff albers
john shiver
medullary thyroid cancer
moderna therapeutics
mrna
new york blog main
new york top stories
What
cancer
3
×
medicines
3
×
drug
approval
bets
bio
blueprint
candidate
comes
companies
currently
cut
date
deal
despite
effective
enticed
evidence
family
fda
hardest
hasn’t
hit
hottest
hunters
ipo
latest
marketing
messenger
molecules
mrna
multiple
muscle
new
pact
pharmaceutical
primarily
promise
proteins
proven
Language
unset
Current search:
medicines
×
deals
×
cancer
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines